I think Mika and the rest of senior management believed what they were saying about the move to the NAS.

There are dozens and dozens of developmental biotechs on the NAS that have never had revenue and many of them have done well share price wise in anticipation of an approvals drug, even though years off. They flourish on the basis of successful early trials, even though those trisls are probably less indicative of ultimate success than some of the recent news coming from Poet. 

Let's not forget that many here were clamoring for the NAS before any mention of "position of strength."

Also, what would senior management have to gain by going on the NAS intentionally prematurely?  Was their hope that the price would spike affording a selling opportunity?  That was a small window of opportunity- I think the price jumped for about 5 minutes, relatively speaking.  

Mika's done a very nice job of keeping dilution to a minimum - pretty significant stuff.  

The promotion of the company, that's on Shelton, unless they've been lobbying for what many here envision and Poet's been refusing to follow their recs.